Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus UTICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus UTICORT.
CAPEX vs UTICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Uticort (betamethasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected area twice daily. Maximum 50 g per week. For short-term use only (≤2 weeks).
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 6-12 hours in hepatic impairment.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% via enterohepatic circulation.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid